Allos Therapeutics Evenly Poised, but Competition Lurks

Zacks.com submits: We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $29.00.

By Bob's Stocks: Alimera Sciences (ALIM) is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina.

Zacks.com submits: We are maintaining our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $44.00.

Zacks.com submits: Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone.

Zacks.com submits: Santarus Inc. (SNTS) recently announced the launch of the over-the-counter [OTC] version of its flagship product, Zegerid. OTC Zegerid is being promoted in North America by Merck's (MRK)consumer Care Products Inc.

Zacks.com submits: In an attempt to guard itself against hostile takeover, Cell Therapeutics (CTIC) adopted a shareholder rights plan. The plan, to be effective from Jan 7, 2010, has been designed so that a potential buyer has to discuss any offer with Cell Therapeutics' board of directors before approaching the shareholders directly.

We are maintaining our Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $0.25. Cell Therapeutics, based in Seattle, Washington, is focused on developing drugs for cancer.

Zacks.com submits: April is crucial for Cell Therapeutics (CTIC), as the U.S. Food and Drug Administration (FDA) decides on the approvability of pixantrone by April 23, 2010.